LG Life Sciences recently announced the start of phase III clinical trials for its Humira® (adalimumab) biosimilar in South Korea. The clinical trials will test the effectiveness of the biosimilar on rheumatoid arthritis patients who have shown negative responses to the chemotherapy drug methotrexate. The trials will also compare the efficacy and safety of the biosimilar to Humira®.
The Korea Herald reports that LG Life Sciences expects to market its biosimilar by 2018 in South Korea and in Japan through its licensing partner, Mochida Pharmaceutical.
